What question did this study set out to answer?

This research aims to assess the efficacy of crizotinib in patients with MET amplification and MET exon 14 skipping mutations.

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

View Full Paper

Ask AI

Bookmark

This research aims to assess the efficacy of crizotinib in patients with MET amplification and MET exon 14 skipping mutations.
Enrolled patients with confirmed MET alterations via Oncomine assay, RNA-sequencing, and Anchored Multiplex PCR.
Administered 250 mg crizotinib orally daily until disease progression or toxicity was observed.
Evaluated objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) as primary and secondary endpoints.
In subprotocol C1, 28 patients were analyzed; ORR was 14% (4/28).
Median PFS was 3.4 months and median OS was 7.1 months in C1.
In subprotocol C2, 14 patients were evaluated; ORR was also 14% (2/14) with median PFS at 2.0 months and median OS at 10.2 months.
Patients with METex14 and a read count ≥50,000 had significantly improved PFS of 8.8 months.

No takes yet. Share an insight, caveat, or question.

The NCI-MATCH trial evaluates crizotinib's effectiveness in tumors with MET alterations, suggesting potential benefits.

Coleman et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark